Xencor (NASDAQ:XNCR – Free Report) had its target price raised by Wedbush from $30.00 to $45.00 in a report issued on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also commented on XNCR. Barclays set a $45.00 price objective on Xencor and gave the stock an “overweight” rating in a research note on Monday. Wells Fargo & Company raised their target price on Xencor from $30.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday. Raymond James Financial lifted their price target on Xencor from $40.00 to $46.00 and gave the company a “strong-buy” rating in a report on Tuesday, September 1st. Bank of America lifted their price target on Xencor from $20.00 to $26.00 and gave the company a “neutral” rating in a report on Monday, September 21st. Finally, Truist Financial reiterated a “buy” rating and set a $29.00 price target (up from $27.00) on shares of Xencor in a research report on Monday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and a consensus target price of $39.33.
Get Our Latest Research Report on XNCR
Xencor Stock Performance
Shares of NASDAQ XNCR opened at $29.21 on Tuesday. Xencor has a one year low of $10.38 and a one year high of $33.60. The business has a fifty day simple moving average of $25.68 and a 200 day simple moving average of $16.89.
Xencor (NASDAQ:XNCR – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. The firm had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%. The business’s revenue was up 17.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.41) earnings per share. Analysts predict that Xencor will post -3.05 earnings per share for the current year.
Institutional Trading of Xencor
A number of large investors have recently made changes to their positions in the company. Integrated Wealth Concepts LLC acquired a new stake in Xencor in the 2nd quarter valued at approximately $30,000. Allworth Financial LP bought a new position in shares of Xencor during the 2nd quarter worth approximately $55,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Xencor during the 3rd quarter worth approximately $95,000. GAMMA Investing LLC raised its holdings in shares of Xencor by 15.5% in the third quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 572 shares during the last quarter. Finally, Pinnacle Wealth Planning Services Inc. raised its holdings in shares of Xencor by 31.0% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 5,804 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 1,373 shares during the last quarter.
About Xencor
Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.
Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.
Read More
- Five stocks we like better than Xencor
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
